INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Similar documents
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use

Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013

EDQM and European Pharmacopoeia: State-of-the-art Science for Tomorrow s Medicines

General concepts in the Ph. Eur.: theory and rationale

Kazuhiko Mori Ministry of Health, Labour and Welfare

Recognized Pharmacopoeia in Registration system

Work plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2018

ICH HARMONISED TRIPARTITE GUIDELINE STABILITY DATA PACKAGE FOR REGISTRATION APPLICATIONS IN CLIMATIC ZONES III AND IV Q1F

Agenda. The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Pharmaceutical Excipients

Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium

Discussion by HMPC Drafting Group on Quality February Start of public consultation 27 June 2012

Measuring Emissions as Part of a Regulatory Regime. Prof. Riccardo Polosa Professor of Internal Medicine and Convenor CEN TC437/WG4

Residual Solvents: FDA/ Regulatory Perspective

Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations

ICH M4E(R2): Revised Guideline on Common Technical Document -- Efficacy

USP NF General Chapter <905> Uniformity of Dosage Units

COMMISSION REGULATION (EU) / of XXX

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

Comparative Studies on Pharmacopoeial Definitions, Requirements and Information for Crude Drugs among FHH Member Countries in 2007

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

On Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents

Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015

State Pharmacopoeia of Ukraine

Organic Impurities in Drug Substances and Drug Products. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017

Indian Pharmacopoeia Commission

Microbiological Quality of Non-sterile Products Culture Media for Compendial Methods

WHITE PAPER ACCESS TO GOOD QUALITY DIETARY SUPPLEMENTS

Announcement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines Act (AMG)

Legal Requirements for the Control of Contaminants in Herbal Medicinal Products and Related Areas

STERILITY TESTING OF PHARMACEUTICAL PRODUCTS

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

Discussion by HMPC Drafting Group on Quality September Start of public consultation 15 February 2013

Pharmakon drug Poiea to make Government of each country List of Pharmacopeias: British European Indian International United state.

Topics covered by the talk

Overview of USP General Chapters <476> and <1086> Prescription/Non-Prescription Stakeholder Forum October 19, 2017

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

COMMISSION DELEGATED REGULATION (EU).../... of XXX

STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7

Guideline on quality of herbal medicinal products 2 /traditional herbal medicinal products

IMPORTANT DISCLAIMER. Note

Guideline on influenza vaccines submission and procedural requirements

Review Article PHARMACEUTICAL EXCIPIENTS: GLOBAL REGULATORY ISSUES

PQRI/USP Workshop on ICH Q3D Elemental Impurities Requirements Recent Experience and Plans for Full Implementation in 2018

Overview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

General Chapter/Section: <232> Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No.

DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)

Draft Guidance for Pharmacists on Extemporaneous Dispensing. Version 1

AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)

The International Pharmacopoeia - Overview

Expectations for Implementation in Europe

H e r b a l M e dicines' Q U A L I T Y M ANUAL. I. Introduction

QUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS

Organisations and/or individuals

Perspectives on alternatives to thiomersal

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

Regulation of FMD vaccines within the European Union

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

Co-processed Excipient Guide

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) POINTS TO CONSIDER ON THE JUSTIFICATION OF HOMEOPATHIC USE

Scientific and Regulatory Basis for Development, Quality Assurance and Marketing Authorisation

COMMISSION IMPLEMENTING DECISION. of XXX

Blanka Hirschlerová. EDQM CEP conference Prague, Czech Republic

USP Perspective on Atypical Actives November 29, 2017

UPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

Potential Grounds for Revocation of a Traditional Herbal Registration

Guide to Registration of Homeopathic Veterinary Medicinal Products

REGULATIONS IN FOOD INGREDIENTS

Herbal summaries for the public

Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the

ECHA Committee for Risk Assessment: Evaluation of the Classification and Labelling of Glyphosate

Update on JP-TW OTC drugs WG

CHAPTER 3. Union Referral Procedures MAY 2014

ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam

Regulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017

a practical guide ISO 13485:2016 Medical devices Advice from ISO/TC 210

Validation Introduction. Presented by John Montalto 27 March, 2013

Caption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

Application for the deletion of bevacizumab (Avastin ) on the WHO Model List of Essential Medicines

COMMISSION REGULATION (EU)

- Notification to specify uniform limit (Ministry of Health, Labour and Welfare Notification No. 497, 2005)

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities

Points to Consider CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Public Assessment Report Scientific discussion

Public Assessment Report Scientific discussion. Rosuvastatin/Amlodipine 10 mg/5 mg, 10 mg/10 mg, 20 mg/5 mg and 20 mg/10 mg film-coated tablets

J Pharm Sci Bioscientific Res (4): ISSN NO

a practical guide Medical Devices Advice from ISO/TC 210 This is a free 11 page sample. Access the full version online.

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

VICH GL58 Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV

Transcription:

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON MICROBIOLOGICAL EXAMINATION OF NON-STERILE PRODUCTS: MICROBIAL ENUMERATIONS TESTS GENERAL CHAPTER Q4B ANNEX 4A(R1) Current Step 4 version dated 27 September 2010 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.

Q4B Annex 4A(R1) Document History Code History Date Q4B Annex 4A Approval by the Steering Committee under Step 2 and release for public consultation. 5 June 2008 Q4B Annex 4A Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 12 November 2008 Current Step 4 version Q4B Annex 4A(R1) Integration of the Health Canada Interchangeability Statement under Section 4.5 after approval by the Steering Committee. 27 September 2010

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON MICROBIOLOGICAL EXAMINATION OF NON-STERILE PRODUCTS: MICROBIAL ENUMERATIONS TESTS GENERAL CHAPTER ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 12 November 2008, this guideline is recommended for adoption to the three regulatory parties to ICH (This annex was revised -R1- to include the Interchangeability Statement from Health Canada on September 27, 2010) TABLE OF CONTENTS 1. INTRODUCTION... 1 2. Q4B OUTCOME... 1 2.1 Analytical Procedures... 1 2.2 Acceptance Criteria... 1 3. TIMING OF ANNEX IMPLEMENTATION... 1 4. CONSIDERATIONS FOR IMPLEMENTATION... 1 4.1 General Consideration... 1 4.2 FDA Consideration... 1 4.3. EU Consideration... 2 4.4 MHLW Consideration... 2 4.5 Health Canada Consideration... 2 5. REFERENCES USED FOR THE Q4B EVALUATION... 2 i

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON MICROBIOLOGICAL EXAMINATION OF NON-STERILE PRODUCTS 1. INTRODUCTION MICROBIAL ENUMERATIONS TESTS GENERAL CHAPTER This annex is the result of the Q4B process for Microbiological Examination of Non- Sterile Products: Microbial Enumeration Tests. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG). 2. Q4B OUTCOME 2.1 Analytical Procedures The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, Ph.Eur. 2.6.12. Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests, JP 4.05 Microbiological Examination of Non-Sterile Products: I. Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests, and USP <61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests can be used as interchangeable in the ICH regions. 2.2 Acceptance Criteria The proposed texts evaluated did not contain acceptance criteria. 3. TIMING OF ANNEX IMPLEMENTATION When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region. 4. CONSIDERATIONS FOR IMPLEMENTATION 4.1 General Consideration When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes. 4.2 FDA Consideration Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method. 1

Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter 4.3. EU Consideration For the European Union, the monographs of the Ph. Eur. have mandatory applicability. Regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 2.6.12. on the basis of the declaration of interchangeability made above. 4.4 MHLW Consideration The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented. 4.5 Health Canada Consideration In Canada, any of the texts cited in section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable. 5. REFERENCES USED FOR THE Q4B EVALUATION 5.1 The PDG Stage 5B sign-off document: Japanese Pharmacopoeial Forum, Volume 14, Number 4 (December 2005). 5.2 The pharmacopoeial references for Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests for this annex are: 5.2.1 European Pharmacopoeia (Ph. Eur.): 6.3 Edition (official on January 2009) Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests (reference 01/2009: 20612); 5.2.2 Japanese Pharmacopoeia (JP): 4.05 Microbiological Examination of Non- Sterile Products: I. Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests as it appears in Supplement I to the Japanese Pharmacopoeia Fifteenth Edition (September 28, 2007, The Ministry of Health, Labour and Welfare Ministerial Notification No. 316). The English version was published on January 9, 2008; 5.2.3 United States Pharmacopeia (USP): <61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests official in USP 30, January 2007. 2